Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.55 USD
0.00 (0.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Milestone Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 66 | 65 | 114 | 142 | 120 |
Receivables | 3 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 6 | 5 | 6 | 2 |
Total Current Assets | 73 | 72 | 119 | 149 | 123 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 75 | 74 | 120 | 150 | 123 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 6 | 7 | 6 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 7 | 6 | 7 | 6 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 50 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 58 | 8 | 7 | 7 | 9 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 261 | 274 | 252 | 252 | 226 |
Capital Surplus | 34 | 24 | 16 | 9 | 4 |
Retained Earnings | -326 | -266 | -206 | -163 | -114 |
Other Equity | 48 | 34 | 51 | 46 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 66 | 113 | 143 | 115 |
Total Liabilities & Shareholder's Equity | 75 | 74 | 120 | 150 | 123 |
Total Common Equity | 17 | 66 | 113 | 143 | 115 |
Shares Outstanding | 33.40 | 34.20 | 29.80 | 29.80 | 24.40 |
Book Value Per Share | 0.50 | 1.94 | 3.78 | 4.80 | 4.71 |
Fiscal Year End for Milestone Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 83 | 89 | 66 | 76 | 88 |
Receivables | 2 | 1 | 3 | 2 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 3 | 4 | 8 | 6 |
Total Current Assets | 87 | 94 | 73 | 85 | 95 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 89 | 96 | 75 | 87 | 97 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 7 | 8 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 5 | 4 | 7 | 8 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 52 | 51 | 50 | 49 | 48 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 57 | 56 | 58 | 59 | 57 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 288 | 288 | 261 | 261 | 260 |
Capital Surplus | 37 | 35 | 34 | 32 | 29 |
Retained Earnings | -346 | -336 | -326 | -312 | -297 |
Other Equity | 53 | 53 | 48 | 48 | 48 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 32 | 40 | 17 | 29 | 40 |
Total Liabilities & Shareholder's Equity | 89 | 96 | 75 | 87 | 97 |
Total Common Equity | 32 | 40 | 17 | 29 | 40 |
Shares Outstanding | 53.20 | 53.10 | 33.40 | 33.30 | 33.30 |
Book Value Per Share | 0.60 | 0.75 | 0.50 | 0.86 | 1.21 |